Trials / Not Yet Recruiting
Not Yet RecruitingNCT07115706
JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD
A Multi-center Prospective Observational Study to Evaluate the Effectiveness and Safety of JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive Gastroesophageal Reflux Disease
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,150 (estimated)
- Sponsor
- Jeil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.
Detailed description
Multi-center prospective observational study
Conditions
Timeline
- Start date
- 2025-08-25
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2025-08-11
- Last updated
- 2025-08-14
Source: ClinicalTrials.gov record NCT07115706. Inclusion in this directory is not an endorsement.